Kinase inhibitors

A compound represented by Formula I, its enantiomers, diastereoisomers, tautomers, or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is hydrogen, substituted or unsubstituted C1-12 alkyl, halogen, or NR9R10;
• R2 is hydrogen or NH2;
• R3 is represented by one of the formulae below:
• Z1 is (CR4R5)n;
• Z2 is (CR6R7)m;
• Y is N;
• n is 2;
• m is 1;
• R4 is hydrogen or substituted or unsubstituted C1-7 alkyl;
• R5 is hydrogen or substituted or unsubstituted C1-7 alkyl;
• R6 is hydrogen or substituted or unsubstituted C1-7 alkyl;
• R7 is hydrogen or substituted or unsubstituted C1-7 alkyl;
• R9 is hydrogen, substituted or unsubstituted C1-7 alkyl, substituted or unsubstituted aryl, or together with the N and R10 can form a substituted or unsubstituted heterocyclic ring;
• R10 is hydrogen, substituted or unsubstituted C1-7 alkyl or together with the N and R9 can form a substituted or unsubstituted heterocyclic ring;
• R14 is hydrogen, substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted heterocycle or substituted or unsubstituted aryl;
• R15 is hydrogen, substituted or unsubstituted C1-7 alkyl, halogen or trifluoromethyl;
• R16 is hydrogen, substituted or unsubstituted C1-7 alkyl, halogen or trifluoromethyl;
• R17 is hydrogen, substituted or unsubstituted C1-7 alkyl, halogen or trifluoromethyl.